When it comes to etiology and treatment of chronic pelvic pain, one size doesn't fit all.
UPOINT helps us recognize that, when it comes to etiology and treatment of CPP, one size doesn't fit all. The constellation of complaints calls for treatment directed specifically at them. In our practices, we phenotype other conditions we treat, such as prostate cancer, where stage, Gleason score, and other factors determine the treatments we apply. It makes sense to do likewise for urologic CPP. Moreover, treating patients in clinical trials without phenotyping has likely made it difficult to show any efficacy because the population at risk may have had a limited number of patients with the symptoms the therapy targets.
As a symptom-based phenotyping system, UPOINT is a good first step toward what we need. The next step is to build the evidence base by applying the system in rigorous, double-blind, controlled studies to see if directed therapy provides real benefit.
High levels of the chemokines MIP and MCP, which suggest prostatic abnormality, have been associated with some chronic pelvic pain syndrome patients and might fulfill this role. Work to further delineate phenotypes with biological markers, using central nervous system imaging, for example, is one of the goals of the Multidisciplinary Approach to the Study of Chronic Pain (MAPP) Research Network.
The UPOINT system is a step in the right direction, paving the way for better-directed treatment and better-controlled clinical trials. At the same time, it doesn't reduce the need to develop more secure biomarkers and to understand the pathophysiology of the condition so that, ultimately, therapies can be directed at pathophysiology.
Dr. Schaeffer, a member of the Urology Times Editorial Council, is professor and chairman of the department of urology at the Northwestern University Feinberg School of Medicine, Chicago.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.